VIVO - Meridian Bioscience, Inc.
| Previous Close | 9.82 |
| Open | 9.85 |
| Bid | 9.87 x 1400 |
| Ask | 9.88 x 2200 |
| Day's Range | 9.80 - 10.00 |
| 52 Week Range | 8.96 - 19.84 |
| Volume | 243,591 |
| Avg. Volume | 287,009 |
| Market Cap | 421.562M |
| Beta (3Y Monthly) | 0.27 |
| PE Ratio (TTM) | 16.45 |
| EPS (TTM) | 0.60 |
| Earnings Date | Nov 8, 2017 - Nov 13, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2019-02-01 |
| 1y Target Est | 10.67 |
- Simply Wall St.
Boasting A 14% Return On Equity, Is Meridian Bioscience, Inc. (NASDAQ:VIVO) A Top Quality Stock?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- Zacks
Should Value Investors Pick Meridian Bioscience (VIVO) Now?
Let's see if Meridian Bioscience (VIVO) stock is a good choice for value-oriented investors right now from multiple angles.
- Thomson Reuters StreetEvents
Edited Transcript of VIVO earnings conference call or presentation 30-Jul-19 2:00pm GMT
Q3 2019 Meridian Bioscience Inc Earnings Call
Motley FoolMeridian Bioscience Inc (VIVO) Q3 2019 Earnings Call Transcript
VIVO earnings call for the period ending June 30, 2019.
- Zacks
Meridian Bioscience (VIVO) Beats Q3 Earnings Estimates
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 60.00% and -2.76%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Meridian Bioscience Reports Third Quarter 2019 Operating Results
CINCINNATI, Ohio, July 30, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter and first nine months ended June 30, 2019..
- Zacks
Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Meridian Bioscience to Hold Third Quarter 2019 Financial Results Conference Call on July 30, 2019
CINCINNATI, July 10, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report third quarter 2019.
CNW GroupInMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors
OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis technology for cannabinoid-based pharmaceuticals to treat severe diseases, today announced the appointment of Catherine Sazdanoff , JD, to its Board of Directors. Ms. Sazdanoff joins InMed's Board with 35 years of experience in the healthcare industry.
- Insider Monkey
Here’s What Hedge Funds Think About Meridian Bioscience, Inc. (VIVO)
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc. (NASDAQ:VIVO) was in […]
- American City Business Journals
One of Cincinnati’s largest public company’s closes on $50M acquisition
Meridian Bioscience has completed a cash acquisition of a Canadian provider of molecular diagnostic instruments and assays.
- GlobeNewswire
Meridian Bioscience Announces Closing of Transaction to Acquire Business of GenePOC
CINCINNATI, June 03, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has.
- Simply Wall St.
Meridian Bioscience, Inc. (NASDAQ:VIVO) Earns Among The Best Returns In Its Industry
Today we are going to look at Meridian Bioscience, Inc. (NASDAQ:VIVO) to see whether it might be an attractive...
- Market Realist
How Does Planet 13’s Valuation Multiple Compare with Peers?
Why Planet 13 Stock Fell ~6.8% on May 7(Continued from Prior Part)Valuation multipleThe increase in Planet 13 Holdings (PLTH) (PLNHF) stock price since the beginning of 2019 has led to a rise in its valuation multiple. As of May 7, the company was
- Thomson Reuters StreetEvents
Edited Transcript of VIVO earnings conference call or presentation 30-Apr-19 2:00pm GMT
Q2 2019 Meridian Bioscience Inc Earnings Call
- American City Business Journals
Cincinnati public company could pay $120M for Canadian firm
One of Greater Cincinnati’s largest public companies is planning an acquisition that could have a price tag of up to $120 million.
- Business Wire
Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition
Meridian Bioscience, Inc. today announced financial results for the second quarter and first six months ended March 31, 2019.
- Zacks
Meridian Bioscience (VIVO) Q2 Earnings and Revenues Top Estimates
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 26.67% and 0.46%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Meridian Bioscience Announces Agreement to Acquire Business of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform
Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has entered into a definitive agreement to acquire the business of GenePOC Inc., a Quebec City, Quebec, Canada based provider of molecular diagnostic instruments and assays. Founded in 2007, GenePOC has approximately 100 employees and generated total revenues of less than $1 million in calendar 2018. Meridian has agreed to make a cash payment at closing of the transaction of $50 million with future payments totaling up to an additional $70 million contingent upon the successful achievement of certain technical development milestones and sales thresholds.
- Associated Press
Meridian Bioscience: Fiscal 2Q Earnings Snapshot
On a per-share basis, the Cincinnati-based company said it had profit of 17 cents. Earnings, adjusted for costs related to mergers and acquisitions and non-recurring costs, were 19 cents per share. The ...
- Simply Wall St.
A Look At The Intrinsic Value Of Meridian Bioscience, Inc. (NASDAQ:VIVO)
Does the April share price for Meridian Bioscience, Inc. (NASDAQ:VIVO) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's val...
